Liteza Cream is a topical formulation containing Hydroquinone (2% w/w), Mometasone (0.1% w/w), and Tretinoin (0.025% w/w), designed for the treatment of hyperpigmentation disorders such as melasma, post-inflammatory hyperpigmentation, and other pigmentary abnormalities. Hydroquinone acts as a depigmenting agent by inhibiting tyrosinase, thereby reducing melanin synthesis and promoting gradual lightening of hyperpigmented areas. Mometasone, a potent corticosteroid, provides anti-inflammatory and immunosuppressive effects, helping to reduce erythema, edema, and irritation associated with pigmentary conditions. Tretinoin, a retinoid derivative, facilitates epidermal cell turnover and enhances the penetration of hydroquinone, contributing to the normalization of keratinization and improvement in skin texture. The combination of these active ingredients offers a synergistic approach to managing stubborn pigmentation by targeting multiple pathogenic pathways. Liteza Cream should be applied once daily to the affected areas, preferably at night, under medical supervision to monitor for potential side effects such as skin irritation, dryness, or steroid-related adverse reactions. It is contraindicated in patients with hypersensitivity to any component and should be used cautiously in individuals with sensitive skin or underlying dermatological conditions. Sun protection is essential during treatment to prevent exacerbation of pigmentation.